Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT01481025Phase 3Unknown
Phase 3, randomised, double-blind trial of hypericum perforatum in perimenopause (3 arms), sponsored by Phytopharm Consulting. Primary endpoint: Menopause Rating Scale at 8 months. Status: unknown.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT01481025.